This document summarizes pharmacological treatment of vitreo-macular traction using ocriplasmin. It defines vitreo-macular traction and adhesion and describes the natural history if left untreated. It outlines the development of ocriplasmin from autologous plasmin to a recombinant form, and phase I-III clinical trial results demonstrating its safety and ability to resolve vitreo-macular adhesion in 26.5% of cases compared to 10.1% for placebo. Potential indications include focal vitreo-macular traction, symptomatic vitreo-macular adhesion, and small non-full thickness or full thickness macular holes.